| Indication | Type 2 Diabetes, Chronic Weight Management |
| Access | Prescription Only (Rx) |
| Dosing schedule | Once Weekly (Subcutaneous) or Daily (Oral) |
| Safety Profile | Moderate (frequent gastrointestinal adverse effects) |
| Key Markers | HbA1c, Body Weight, eGFR |
| Est. Cost | Variable (without insurance coverage) |
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists represent a class of peptide therapeutics. Primarily designed to address type 2 diabetes mellitus and chronic weight management, these agents act through metabolic, cardiovascular, and neurological pathways to drive improvements in glycemic control, lipid profiles, visceral adiposity, and cardiorenal outcomes, backed by randomized controlled trials.
WARNING: THYROID CANCER CONCERNS
In animal studies and drug database analyses, concerns have been raised regarding a potential association with thyroid cancer. While several meta-analyses have failed to confirm a causal relationship in humans, clinicians should exercise caution in patients at risk.[1]
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release.[9][2:2] Dual GIP/GLP-1 receptor agonists represent a class of therapeutics that simultaneously target the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor.[2:3]
While sharing overlapping clinical indications, these two classes feature distinct pharmacological designs:
These agents produce reductions in hemoglobin A1c (HbA1c) and blood glucose levels in patients with type 2 diabetes, improving glycemic control.[9:1][2:7]
Chronic administration leads to reductions in body weight and adipose tissues:
Cardiovascular protection is a property of these therapeutic classes, demonstrated across large clinical trials:
| Outcome / Goal | Effect | Consistency | Evidence quality | Trials | Notes (population, duration) |
|---|---|---|---|---|---|
| Glycemic Control | Reduction | High | High | SURPASS, SUSTAIN | Reduces HbA1c in type 2 diabetes.[9:3][2:8] |
| Weight Management | Weight Loss | High | High | STEP, SURMOUNT | Significant weight loss demonstrated over 68–72 weeks.[4:3][5:3] |
| MACE Reduction (Diabetic) | Reduction | High | High | SUSTAIN-6 | Reduces major adverse cardiovascular events in T2DM.[10:1] |
| MACE Reduction (Non-Diabetic) | Reduction | High | High | SELECT | Reduces major adverse cardiovascular events in overweight/obese adults.[6:3] |
| Renal Protection | Protection | High | High | FLOW | Reduces major kidney disease events in T2DM and CKD.[7:2] |
| Sleep Apnea Reduction | Reduction | High | High | SURMOUNT-OSA | Reduces apnea-hypopnea events in adults with obesity and moderate-to-severe obstructive sleep apnea.[16] |
| Gastrointestinal Symptoms | Increase (Adverse Effect) | High | High | Class-wide trials | Gastrointestinal adverse events are common and occur primarily during dose escalation.[1:2][5:4] |
In healthy physiology, the ingestion of nutrients triggers the release of the incretin hormones GLP-1 and GIP.[2:9] These hormones bind to specific receptors on pancreatic beta cells to stimulate glucose-dependent insulin secretion, meaning insulin release is primarily stimulated in the presence of elevated blood glucose levels.[2:10]
In dual GIP/GLP-1 receptor agonism, the molecule acts as an agonist at both GIP and GLP-1 receptors.[2:11] GIP and GLP-1 regulate food intake by stimulating neurons in the brain's satiety center, and regulate lipogenesis and lipolysis to maintain healthy adipocytes.[2:12]
These peptides act on central receptors to promote satiety, suppress hunger, and modulate central reward pathways, which may reduce cravings.[2:13][15:1]
These agents delay gastric emptying, which can increase the propensity for longer intragastric retention of food.[3:1]
To minimize gastrointestinal adverse effects, pharmacotherapy with long-acting incretin-based agents typically begins at lower initiation doses followed by a dose-escalation protocol, with adverse events occurring primarily during titration.[5:5]
In clinical settings, treatment efficacy is characterized by changes in key metabolic parameters, specifically blood glucose levels (and HbA1c) in patients with type 2 diabetes, and body weight in patients undergoing weight management.[9:4][2:14][4:4]
GI symptoms are the most common adverse events, occurring in the majority of patients:
Gallbladder-related events, such as cholelithiasis, have been reported in clinical trials, with cases observed during active therapy.[17:1]
Acute pancreatitis has been observed in clinical trials and post-marketing reports, although several meta-analyses have failed to confirm a clear cause-and-effect relationship.[1:4]
Case reports have linked the use of these drugs with the occurrence of acute kidney injury, primarily through hemodynamic derangement secondary to severe gastrointestinal adverse effects such as vomiting and diarrhea.[1:5]
GLP-1 receptor agonist use has been associated with an increased risk of early-stage diabetic retinopathy and early-stage retinal adverse events compared to placebo.[21] Furthermore, global pharmacovigilance database analyses have identified potential ocular safety signals associated with certain GLP-1 receptor agonists, including reports of visual impairment, blurred vision, and non-arteritic anterior ischemic optic neuropathy (NAION).[22][23][24][25]
When used as monotherapy, GLP-1 receptor agonists and dual agonists carry a low risk of hypoglycemia. However, if these agents are added to a regimen containing insulin or sulfonylureas, the risk of severe hypoglycemia increases, necessitating dose adjustment of background therapies.[1:6]
Due to delayed gastric emptying, there is a potential risk of retained gastric contents, which may increase the risk of pulmonary aspiration during procedures requiring anesthesia or upper gastrointestinal endoscopy.[3:2] However, the development of definitive pre-procedural guidelines remains compromised by a limited and poor evidence base, particularly regarding long-acting formulations.[3:3]
Subcutaneous semaglutide is utilized for weight management in pediatric and adolescent patients with obesity, demonstrating significant body mass index reduction.[17:2][29]
Clinicians should monitor for potential loss of muscle and bone mass during therapy, as the functional implications of these losses and weight regain upon discontinuation remain critical open questions.[9:5]
In patients with type 2 diabetes and chronic kidney disease, semaglutide reduced the progression of major kidney disease events.[7:3]
Practitioners should remain vigilant for neuropsychiatric symptoms, as some pharmacovigilance reports suggest signals of depressive disorders and suicidal ideation with certain agents, although cohort studies do not consistently demonstrate an increased risk.[30][31][22:1]
The clinical utilization of GLP-1 receptor agonists such as Ozempic, Wegovy, and Mounjaro has experienced a rapid and exponential transition, highlighting substantial clinical demand.[32] However, access remains a key challenge; clinical evaluations discuss the dangers of perpetuating health inequities if access to these therapies remains biased,[29:1] and patients may face additional out-of-pocket costs when these agents are not subsidized or covered.[27:1]
Due to high demand and clinical interest, off-label prescribing is common.[27:2] Prescribing medications in a manner that is not concordant with approved product indications can carry an increased risk of prescriber liability if patients experience adverse events, particularly when clinical guidelines are lacking.[27:3] Prescribers should ensure patients are informed of potential benefits, harms, and any additional costs associated with off-label use.[27:4]
Clinical trials show that weight loss and glycemic benefits are highly treatment-dependent. Following drug discontinuation or switching to placebo, patients typically experience weight regain and reversal of metabolic improvements.[8:1]
In animal models and drug database analyses, concerns have been raised regarding a potential association with thyroid cancer.[1:7] However, several meta-analyses have failed to confirm a causal relationship in humans.[1:8]
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014). Adverse Effects of GLP-1 Receptor Agonists. The Review of Diabetic Studies, 11(3), 202-215. https://pubmed.ncbi.nlm.nih.gov/26177483/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Liu, Q. K. (2024). Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Frontiers in Endocrinology, 15, 134256. https://pubmed.ncbi.nlm.nih.gov/39114288/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Jalleh, R. J., Rayner, C. K., & Hausken, T. (2024). Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. The Lancet Gastroenterology & Hepatology, 9(10), 910-921. https://pubmed.ncbi.nlm.nih.gov/39096914/ ↩︎ ↩︎ ↩︎ ↩︎
Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1001. https://pubmed.ncbi.nlm.nih.gov/33567185/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Aronne, L. J., et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine, 393(1), 15-27. https://pubmed.ncbi.nlm.nih.gov/40353578/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Lincoff, A. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/ ↩︎ ↩︎ ↩︎ ↩︎
Collister, D., Pannu, N., et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. Annals of Internal Medicine, 181(3), 109-121. https://pubmed.ncbi.nlm.nih.gov/39222509/ ↩︎ ↩︎ ↩︎ ↩︎
Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414-1425. https://pubmed.ncbi.nlm.nih.gov/33755728/ ↩︎ ↩︎
Rosen, C. J., & Ingelfinger, J. R. (2026). GLP-1 Receptor Agonists. New England Journal of Medicine, 394(14), 1310-1322. https://pubmed.ncbi.nlm.nih.gov/41931049/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Marso, S. P., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834-1844. https://pubmed.ncbi.nlm.nih.gov/27633186/ ↩︎ ↩︎
Loomba, R., et al. (2024). Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. New England Journal of Medicine, 391(4), 299-310. https://pubmed.ncbi.nlm.nih.gov/38856224/ ↩︎
Zhao, X., Wang, M., & Wen, Z. (2021). GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Frontiers in Endocrinology, 12, 643450. https://pubmed.ncbi.nlm.nih.gov/34497589/ ↩︎
Cummings, J. L., Atri, A., & Sano, M. (2026). Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. The Lancet, 407(10543), 1811-1823. https://pubmed.ncbi.nlm.nih.gov/41865758/ ↩︎ ↩︎
Jerlhag, E. (2025). GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder. Endocrinology, 166(2), bvae201. https://pubmed.ncbi.nlm.nih.gov/39980336/ ↩︎
Amorim Moreira Alves, G., Teranishi, M., & Teixeira de Castro Gonçalves Ortega, A. C. (2025). Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological and Translational Insights. Medical Sciences, 13(8), 101-112. https://pubmed.ncbi.nlm.nih.gov/40843757/ ↩︎ ↩︎
Cheskin, L. J., & Rajagopal, S. (2024). In adults with moderate-to-severe OSA and obesity, tirzepatide reduced apnea-hypopnea events vs. placebo. Annals of Internal Medicine, 181(10), 1210-1212. https://pubmed.ncbi.nlm.nih.gov/39348697/ ↩︎
Weghuber, D., et al. (2022). Once-Weekly Semaglutide in Adolescents with Obesity. New England Journal of Medicine, 387(24), 2245-2254. https://pubmed.ncbi.nlm.nih.gov/36322838/ ↩︎ ↩︎ ↩︎
Wadden, T. A., et al. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA, 325(14), 1403-1413. https://pubmed.ncbi.nlm.nih.gov/33625476/ ↩︎
Wharton, S., et al. (2025). Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology, 13(1), 15-27. https://pubmed.ncbi.nlm.nih.gov/40961952/ ↩︎
Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. https://pubmed.ncbi.nlm.nih.gov/36216945/ ↩︎
Kapoor, I., Sarvepalli, S. M., & D'Alessio, D. (2023). GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials. Survey of Ophthalmology, 68(6), 1010-1025. https://pubmed.ncbi.nlm.nih.gov/37454782/ ↩︎
Kim, T. H., Lee, K., & Park, S. (2025). Adverse drug reaction patterns of GLP-1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database. Diabetes, Obesity & Metabolism, 27(6), 1450-1462. https://pubmed.ncbi.nlm.nih.gov/40176478/ ↩︎ ↩︎
Cheng, X., Jiang, Z., & Li, G. (2026). Multi-database pharmacovigilance assessment of GLP-1 receptor agonist-related ophthalmic risks using advanced signal detection in FAERS and vigibase. Journal of Endocrinological Investigation, 49(2), 231-242. https://pubmed.ncbi.nlm.nih.gov/41021211/ ↩︎
Zhou, J., Huang, W., & Xie, Y. (2025). Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database. Endocrine, 88(1), 145-156. https://pubmed.ncbi.nlm.nih.gov/39578328/ ↩︎
Massy, M., Marti, S., & Hammer, H. (2025). Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data. BMC Medicine, 23(1), 112-121. https://pubmed.ncbi.nlm.nih.gov/40189538/ ↩︎
Cena, H., Chiovato, L., & Nappi, R. E. (2020). Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. The Journal of Clinical Endocrinology & Metabolism, 105(8), e2995-e3005. https://pubmed.ncbi.nlm.nih.gov/32442310/ ↩︎
Day, R. O. (2023). Ongoing challenges of off-label prescribing. Australian Prescriber, 46(6), 180-182. https://pubmed.ncbi.nlm.nih.gov/38152320/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Skelley, J. W., Swearengin, K., & York, A. L. (2024). The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. Journal of the American Pharmacists Association, 64(1), 101-110. https://pubmed.ncbi.nlm.nih.gov/37940101/ ↩︎
Stefater-Richards, M. A., Jhe, G., & Zhang, Y. J. (2025). GLP-1 Receptor Agonists in Pediatric and Adolescent Obesity. Pediatrics, 155(4), e20241022. https://pubmed.ncbi.nlm.nih.gov/40031990/ ↩︎ ↩︎
Valentino, K., Teopiz, K. M., & Cheung, W. (2025). The effect of glucagon-like Peptide-1 receptor agonists on measures of suicidality: A systematic review. Journal of Psychiatric Research, 183, 102-115. https://pubmed.ncbi.nlm.nih.gov/39956093/ ↩︎
Wang, M., Chen, X., & Liu, Z. (2025). Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data. EClinicalMedicine, 86, 103112. https://pubmed.ncbi.nlm.nih.gov/40777864/ ↩︎
Watanabe, J. H., Kwon, J., & Nan, B. (2024). Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. Journal of the American Pharmacists Association, 64(1), 120-131. https://pubmed.ncbi.nlm.nih.gov/37821008/ ↩︎